Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa

被引:17
|
作者
Berlier, Monique [1 ]
Barry, Rodrigue [2 ]
Shadid, John [3 ]
Sirica, Coimbra [4 ]
Brunier, Alison [5 ]
Hasan, Hayatee [6 ]
Bouma, Enricke [1 ]
机构
[1] PATH, Meningitis Vaccine Project, Ferney Voltaire, France
[2] WHO, Intercountry Support Team West Africa, Ouagadougou, Burkina Faso
[3] UN Childrens Fund, West & Cent Africa Reg Off, Dakar, Senegal
[4] Burness Commun, Bethesda, MD USA
[5] WHO, Dept Commun Capac Bldg, CH-1211 Geneva, Switzerland
[6] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland
关键词
advocacy and communication; messaging; vaccine introduction; meningitis belt; crisis communication; CONJUGATE VACCINE; MENINGITIS; TEMPERATURE; BENEFITS; CHAD;
D O I
10.1093/cid/civ493
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. A new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa. Methods. From the outset of the project, advocacy and communication strategies were developed and adjusted as the project evolved in Europe, Africa, India, and the United States. Communications efforts were evidence-based, and involved partnerships with the media and various stakeholders including African ministries of health, the World Health Organization, UNICEF, Gavi, the Centers for Disease Control and Prevention, and M,decins Sans FrontiSres. Results. The implementation of an integrated communication strategy ensured the active cooperation of stakeholders while providing an organized and defined format for the dissemination of project-related developmental activities and the successful introduction of the vaccine. Conclusions. Early in the project, a communications strategy that engaged stakeholders and potential supporters was developed. The strategy was implemented and adapted as the project matured. Linked communication proved to be key to the successful wide-scale introduction of the PsA-TT (MenAfriVac) vaccine in Africa.
引用
收藏
页码:S451 / S458
页数:8
相关论文
共 50 条
  • [31] Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale
    de Souza, Iaralice Medeiros
    da Silva, Milton Neto
    Bastos, Renata Chagas
    Gomes Pereira, Denise da Silva
    Schott Figueira, Elza Cristina
    Jessouroun, Ellen
    Moura Leal, Maria de Lourdes
    Barreto-Bergter, Eliana
    Freitas Brasileiro da Silveira, Ivna Alana
    GLYCOCONJUGATE JOURNAL, 2021, 38 (05) : 539 - 549
  • [32] Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014
    Djingarey, Mamoudou H.
    Diomande, Fabien V. K.
    Barry, Rodrigue
    Kandolo, Denis
    Shirehwa, Florence
    Lingani, Clement
    Novak, Ryan T.
    Tevi-Benissan, Carol
    Perea, William
    Preziosi, Marie-Pierre
    LaForce, F. Marc
    CLINICAL INFECTIOUS DISEASES, 2015, 61 : S434 - S441
  • [33] A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)
    Koeberling, Oliver
    Ispasanie, Emma
    Hauser, Julia
    Rossi, Omar
    Pluschke, Gerd
    Caugant, Dominique A.
    Saul, Allan
    MacLennan, Calman A.
    VACCINE, 2014, 32 (23) : 2688 - 2695
  • [34] International Dengue Vaccine Communication and Advocacy: Challenges and Way Forward
    Carvalho, Ana
    Van Roy, Rebecca
    Andrus, Jon
    EXPERT REVIEW OF VACCINES, 2016, 15 (04) : 539 - 545
  • [35] MENINGOCOCCAL DISEASE IN THE ISRAEL DEFENSE FORCE - EPIDEMIOLOGIC TRENDS AND NEW CHALLENGES
    GROTTO, I
    BLOCK, C
    LERMAN, Y
    WIENER, M
    ASHKENAZI, S
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1995, 31 (01): : 54 - 58
  • [36] Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines
    Ladhani, Shamez N.
    Flood, Jessica S.
    Ramsay, Mary E.
    Campbell, Helen
    Gray, Stephen J.
    Kaczmarski, Edward B.
    Mallard, Richard H.
    Guiver, Malcolm
    Newbold, Lynne S.
    Borrow, Ray
    VACCINE, 2012, 30 (24) : 3710 - 3716
  • [37] Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages
    Broeker, Michael
    Dull, Peter M.
    Rappuoli, Rino
    Costantino, Paolo
    VACCINE, 2009, 27 (41) : 5574 - 5580
  • [38] Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi
    Bar-Zeev, Naor
    Kapanda, Lester
    King, Carina
    Beard, James
    Phiri, Tambosi
    Mvula, Hazzie
    Crampin, Amelia C.
    Mwansambo, Charles
    Costello, Anthony
    Parashar, Umesh
    Tate, Jacqueline E.
    Verani, Jennifer R.
    Whitney, Cynthia G.
    Heyderman, Robert S.
    Cunliffe, Nigel A.
    French, Neil
    VACCINE, 2015, 33 (23) : 2637 - 2645
  • [39] Meningococcal vaccine development - from glycoconjugates against MenACWY to proteins against MenB - potential for broad protection against meningococcal disease
    Dull, Peter M.
    McIntosh, E. David
    VACCINE, 2012, 30 : B18 - B25
  • [40] Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India
    Kulkarni, Prasad S.
    Socquet, Muriel
    Jadhav, Suresh S.
    Kapre, Subhash V.
    LaForce, F. Marc
    Poonawalla, Cyrus S.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 : S483 - S488